As shown in Fig. 4C,E, the prevention of aripiprazole‐induced AMPK activation observed in the cells treated with D2R antagonists raised the possibility that the D2R/AMPK pathway antagonizes the radiosensitizing effects of aripiprazole against breast cancer cells. Here, PRKAA1 is linked to breast cancer.